Doc logic, I appreciate the thoughtful response and I agree with you on one important point right up front. The recent regulatory environment has changed in a way that makes it smart for Northwest to rebuild the Direct IND now rather than later. Where we differ is on the history of how Direct was actually manufactured and what the term closed system means in the context of current FDA expectations.
For the original Direct trial the company used what everyone at that time called a standard dendritic cell process. Monocytes were isolated from leukapheresis product, cultured and matured ex vivo with manual steps, checked by hand with flow cytometry, washed and then drawn up into syringes for intratumoral injection. The filtration and concentration stage used TFF. That is more contained than some older methods, but it is not what FDA today regards as a fully closed automated manufacturing system. TFF still involves tubing connections, manual transfers, operator adjustment of pumps, and exposure points. It is better than open dishes, but it is not a sealed end to end device that can be qualified as a closed platform.
You can actually see this in the wording of the recent 10Q. Northwest explicitly talks about a choice between TFF and the commercial system, then about transferring the process into the Grade C clean room, validating every piece of equipment after it is placed there, qualifying each operator with repeated aseptic simulations, and running three consecutive PQQ lots at scale. That is exactly the checklist FDA expects when a sponsor takes a process that was previously manual or semi open and moves it onto a modern closed system such as EDEN. If Direct had already been running in a fully closed platform for years there would be no need for that entire sequence of selection, transfer, equipment validation and PQQ. The company would simply reference prior validation. The fact that they had to do all of this tells you that the historic Direct workflow was not considered closed in the way the regulators now use that word.
On the regulatory side the change has not been a single new law that suddenly bans open methods. It has been a steady tightening of the chemistry manufacturing and controls expectations for autologous therapies. Under 21 CFR 312 point 23 the sponsor has always been required to show that its manufacturing and control methods assure identity, quality, purity, strength and safety. Over the last several years FDA has made it very clear in guidances and public workshops that for cell therapies the practical way to satisfy that requirement is to minimize manual handling and rely on closed or functionally closed automated systems. You can still write an IND on a heavily manual process, but in practice it will draw long lists of questions and is unlikely to be accepted for a new trial or for transfer to a new site without major remediation.
That is why the company had to go through the full EDEN validation before it could say in the filing that the manufacturing and product related portions of the Direct IND are complete. The old Direct process with open or semi open handling and TFF could not stand on its own under the modern interpretation of 312 point 23. EDEN turns that craft process into something that is sealed, repeatable, and consistent enough to pass aseptic simulations and PQQ, and to be described as a commercial system in a Grade C environment.
So I think you are right that Northwest is using the updated IND framework to stay ahead of where the regulators are going. The only refinement I would add is that the earlier Direct process was not fully closed by todays regulatory definition, and that is exactly why the company had to install and qualify EDEN and then rebuild the IND around that closed automated platform.
Bullish
AI
Market Data 
Markets 
